Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer
Launched by CANCER TRIALS IRELAND · May 27, 2014
Trial Information
Current as of August 02, 2025
Terminated
Keywords
ClinConnect Summary
Pre-operative radiotherapy (RT) or chemo-radiotherapy (CRT) is internationally accepted as standard practice in the management of locally advanced rectal cancer.
Multiple randomised trials have proved pre-operative CRT and RT, compared to surgery alone, reduce local recurrence, even prior to optimal surgery, and may improve survival for T3 circumferential resection margin (CRM) negative patients.
This study aims to determine if 3-DCRT or IMRT result in lower incidence of grade 2 GI toxicities.
Acute toxicities will be assessed weekly during radiotherapy, and at 2 and 4 week post treatmen...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing pre-operative pelvic chemo-radiotherapy for histologically confirmed rectal adenocarcinoma, with the following staging: cT3N0-2, cT4N0-2, cT(any)N1-2, cT(any)N(any) CRM at-risk \[AJCC version V\]
- • Staging / imaging of pelvis with MRI, and CT Thorax/Abdomen
- • No evidence of metastatic disease
- • ECOG Performance Status 0 - 2
- • Age \> or equal to 18 years
- • Provision of written informed consent in line with ICH-GCP guidelines
- Exclusion Criteria:
- • Previous radiotherapy to the pelvic region
- • Patients in whom induction chemotherapy has been delivered prior to chemo- radiotherapy
- • History of inflammatory bowel disease
- • Previous hip replacement
- • Previous bowel surgery (excluding procedures/operations which would not result in small bowel adhesions - at the discretion of the Principal Investigator)
- • Patients with other syndromes/conditions associated with increased radiosensitivity
- • Any other co-existing malignancies within the past 5 years other than non- melanoma skin cancer
- • Pregnancy or lactation at the time of proposed randomisation
- • Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study or if it is felt by the research / medical team that the patient may not be able to comply with the protocol
About Cancer Trials Ireland
Cancer Trials Ireland is a leading clinical research organization dedicated to advancing cancer treatment through innovative clinical trials. Committed to enhancing patient outcomes, the organization collaborates with a network of healthcare professionals, academic institutions, and industry partners to design and conduct rigorous studies that evaluate new therapies and treatment strategies. With a focus on precision medicine and patient-centric approaches, Cancer Trials Ireland aims to facilitate access to cutting-edge treatments for patients across Ireland, driving progress in cancer research and fostering a culture of excellence in clinical trial management.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dublin, , Ireland
Dublin, , Ireland
Dublin, , Ireland
Patients applied
Trial Officials
Dr Brian O'Neill, MD
Principal Investigator
St Luke's Centre for Radiation Oncology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials